ArticleThe Lancet. Global health2022
Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of measles vaccination strategies on vaccination rates in low-income and middle-income countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Protective antibody response following two doses of measles vaccination and factors for non-response among children from tribal Odisha, India.The Indian journal of medical research · 2026Article
- Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance.Scientific reports · 2026Article
- Timing of antiretroviral treatment initiation and seropositivity to measles virus among children living with HIV in rural Zambia.medRxiv : the preprint server for health sciences · 2026Article
- Low Measles Seropositivity in Vaccinated Children.JAMA network open · 2025Article
- A population-representative serosurvey estimating vaccine-induced immunity against measles, rubella, hepatitis B and severe acute respiratory syndrome coronavirus 2 in Timor-Leste.The Lancet regional health. Southeast Asia · 2025Article
- A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine.Human vaccines & immunotherapeutics · 2024Review
- Measles and rubella seroprevalence in adults using residual blood samples from health facilities and household serosurveys in Palghar District, Maharashtra, India, 2018 - 2019.Epidemiology and infection · 2024Article
- Increased measles and rubella seroprevalence in children using residual blood samples from health facilities and household serosurveys after supplementary immunization activities in two districts in India.Epidemiology and infection · 2024Article
- Challenges and Approaches to Establishing Multi-Pathogen Serosurveillance: Findings from the 2023 Serosurveillance Summit.The American journal of tropical medicine and hygiene · 2024Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- Article
- Experiences and Lessons Learned from the Measles-Rubella Vaccination Campaign 2023 Implemented in Private Schools of Kolkata.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
Abstract
backgroundIndia did phased measles-rubella supplementary immunisation activities (MR-SIAs; ie, mass-immunisation campaigns) targeting children aged 9 months to less than 15 years. We estimated measles-rubella seroprevalence before and after the MR-SIAs to quantify the effect on population immunity and identify remaining immunity gaps.
methodsBetween March 9, 2018 and March 19, 2020 we did community-based, cross-sectional serosurveys in four districts in India before and after MR-SIAs. 30 villages or wards were selected within each district, and one census enumeration block from each was selected as the survey cluster. Households were enumerated and 13 children in the younger age group (9 months to <5 years) and 13 children in the older ager group (5 to <15 years) were randomly selected by use of computer-generated random numbers. Serum samples were tested for IgG antibodies to measles and rubella viruses by enzyme immunoassay.
findingsSpecimens were collected from 2570 children before the MR-SIA and from 2619 children afterwards. The weighted MR-SIA coverage ranged from 73·7% to 90·5% in younger children and from 73·6% to 93·6% in older children. Before the MR-SIA, district-level measles seroprevalence was between 80·7% and 88·5% among younger children in all districts, and between 63·4% and 84·5% among older children. After the MR-SIA, measles seroprevalence among younger children increased to more than 90% (range 91·5 to 96·0) in all districts except Kanpur Nagar, in which it remained unchanged 80·4%. Among older children, measles seroprevalence increased to more than 90·0% (range 93·7% to 96·5%) in all districts except Hoshiarpur (88·7%). A significant increase in rubella seroprevalence was observed in all districts in both age groups, with the largest effect in Dibrugarh, where rubella seroprevalence increased from 10·6% to 96·5% among younger children.
interpretationMeasles-rubella seroprevalence increased substantially after the MR-SIAs but the serosurvey also identified remaining gaps in population immunity.
fundingThe Bill & Melinda Gates Foundation and Indian Council of Medical Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.